ClinicalTrials.gg
RecruitingNCT07409246Updated Oct 20, 2026

A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

A Phase 1 interventional study of ABBV-438 in Multiple Myeloma, sponsored by AbbVie. Recruiting at 14 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.
Updated Oct 20, 20264 sites added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
127
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Multiple Myeloma by AbbVie — 7 open to participants now, 17 under way, 5 of them phase 3. Multiple Myeloma · AbbVie.

Planned enrollment
15th of 39
127 · median 84
Started
2026
with 2 others
Phase 1
18 of 40
3 open now
Primary completion
2031-11
later than 11 of 16 live
Registered
39th of 40
by date

Among the 40 studies in Multiple Myeloma by AbbVie, this one is the 15th largest by planned enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2026, is one of 18 in phase 1, reaches primary completion later than 11 of the 16 other live ones, and was the 39th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

7 of the 40 studies in Multiple Myeloma by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Multiple Myeloma by AbbVie, or all of them as a file.
02

Study summary

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety, tolerability, and how ABBV-438 moves through the body, in adult participants with relapsed/refractory (R/R) MM. Adverse events, tolerability, how ABBV-438 moves through the body will be assessed.

ABBV-438 is an investigational drug being developed for the treatment of R/R MM. Study doctors put the participants in groups called treatment arms broken into 2 parts. ABBV-438 will be given alone and multiple doses will be explored. This study will include a dose escalation phase (Part 1) to determine the best dose of ABBV-438, followed by a dose expansion phase (Part 2) to confirm the dose. Approximately 127 adult participants with R/R MM will be enrolled in the study in approximately 24 sites worldwide.

Participants will receive intravenous (IV) ABBV-438 alone first in multiple doses in the dose escalation phase (Part 1); then in 1 of 2 doses from Part 1 in the dose expansion phase (Part 2). The overall study duration will be approximately 69.5 months.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • Multiple Myeloma
  • ABBV-438
  • Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has Multiple Myeloma (MM) with documented evidence of progression during or after the participant's last treatment regimen based on the investigator's determination of the standard International Myeloma Working Group (IMWG) (2016) response criteria:

    • Relapsed defined as previously treated myeloma that progresses and requires initiation of salvage therapy;
    • Refractory defined as disease that is nonresponsive (failure to achieve minimal response) while on last therapy, or progresses within 60 days of last therapy.
  • Has at screening, defined by at least 1 of the following within 28 days prior to enrollment:

    • Serum M-protein >= 0.5 g/dL (>=5 g/L); OR;
    • Urine M-protein >= 200 mg/24 hours; OR;
    • Involved serum free light chain (sFLC) >= 10 mg/dL (100mg/L), provided serum FLC ratio is abnormal;
    • Must have had 3 or more with exposure to a proteasome inhibitor (PI), an immunomodulatory imide drugs (IMiD), and an anti-CD38 therapy and are intolerant to, or unable to access, available therapies that are known to confer clinical benefit to participants with relapsed or refractory (R/R) MM. Note: A line of therapy consists of relapsed or refractory 1 complete cycle of a single agent, a regimen consisting of a combination of several drugs, or a planned sequential therapy of various regimens.

Exclusion criteria

Exclusion Criteria:

  • Known history of Central Nervous System involvement by MM.
  • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
127 participants (estimated)

Study arms

  • Experimental
    Part 1: ABBV-438 Monotherapy Dose Escalation

    Participants will receive ABBV-438 in escalating doses alone, as part of the 69.5 study duration.

    Drug: ABBV-438

  • Experimental
    Part 2: ABBV-438 Monotherapy Dose Expansion (Dose A)

    Participants will receive ABBV-438 Dose A alone, as part of the 69.5 study duration.

    Drug: ABBV-438

  • Experimental
    Part 2: ABBV-438 Monotherapy Dose Expansion (Dose B)

    Participants will receive ABBV-438 Dose B alone, as part of the 69.5 study duration.

    Drug: ABBV-438

Interventions

  • DrugABBV-438

    Intravenous (IV)

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AE)

    An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) is defined as any untoward medical occurrence, whether associated with study drug or not, that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event requiring medical or surgical intervention to prevent serious outcome.

    Time frame: Up to Approximately 69.5 Months

  2. Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Parameters

    Clinical laboratory parameters included tests of hematology and chemistry. The investigator will assess the results for clinical significance.

    Time frame: Up to Approximately 69.5 Months

  3. Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Parameters

    Vital sign parameters included body temperature, systolic and diastolic blood pressure, pulse rate, and respiratory rate. The investigator will assess the results for clinical significance.

    Time frame: Up to Approximately 69.5 Months

  4. Number of Participants With Clinically Significant Changes From Baseline in Electrocardiograms (ECG)

    A standard 12-lead ECG will be performed. The investigator will assess the results for clinical significance.

    Time frame: Up to Approximately 69.5 Months

Secondary outcomes

  1. Overall Response Rate (ORR)

    ORR is defined as the percentage of participants with the achievement of partial response (PR) or very good partial response (VGPR) or complete response (CR) or stringent complete response (sCR) as assessed by investigators per IMWG 2016 criteria.

    Time frame: Up to Approximately 69.5 Months

  2. Number of Participants Achieving VGPR or Better

    VGPR or better is defined as the percentage of participants with the achievement of VGPR , CR, or sCR as assessed by investigators per IMWG 2016 criteria.

    Time frame: Up to Approximately 69.5 Months

  3. Duration of Response (DOR) in Participants who Achieved PR or VGPR or CR or sCR

    DOR is defined as confirmed sCR, CR, VGPR, or PR as the time from the initial response of PR (or better) per investigator review according to IMWG 2016 criteria, to disease progression or death of any cause, whichever occurs earlier.

    Time frame: Up to Approximately 69.5 Months

  4. Progression-free survival (PFS)

    PFS defined as time from first study treatment to a documented disease progression according to IMWG 2016 criteria, as determined by the investigator, or death due to any cause, whichever occurs earlier.

    Time frame: Up to Approximately 69.5 Months

  5. Overall survival (OS)

    OS is defined as time from first study treatment to death due to any cause.

    Time frame: Up to Approximately 69.5 Months

  6. Area Under the Plasma Concentration-Time Curve (AUC) of ABBV-438

    Area under the plasma concentration-time curve of ABBV-438.

    Time frame: Up to Approximately 69.5 Months

  7. Maximum Observed Plasma Concentration (Cmax) of ABBV-438

    Maximum observed plasma concentration of ABBV-438.

    Time frame: Up to Approximately 69.5 Months

  8. Time to Cmax (Tmax) of ABBV-438

    Time to Cmax of ABBV-438.

    Time frame: Up to Approximately 69.5 Months

  9. t1/2 (Half-life) of ABBV-438

    Half-life of ABBV-438.

    Time frame: Up to Approximately 69.5 Months

07

Study locations

14 of 14 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Nov 2031, 69 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's planned 69 months is above that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2026
First posted
Feb 13, 2026
StartActual
Feb 27, 2026
Primary completionEst.
Nov 2031
CompletionEst.
Nov 2031
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 1 site removed
Show 4 added (2 Japan, 1 China, 1 United States)
  • The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 279207 · Hangzhou, China
  • The Cancer Institute Hospital Of Japanese Foundation for Cancer Research /ID# 279069 · Koto-ku, Japan
  • University of Chicago Medical Center /ID# 278863 · Chicago, United States
  • Tokyo Metropolitan Komagome Hospital /ID# 279070 · Bunkyo Ku, Japan
Show 1 removed
  • The Cancer Institute Hospital Of JFCR /ID# 279069 · Koto-ku, Japan
across 3 updates, Sep 28, 2026 – Oct 20, 2026
Show all 3 updates
  1. Oct 20, 2026
    1 site added
    Show site
    • Tokyo Metropolitan Komagome Hospital /ID# 279070 · Bunkyo Ku, Japan
    + 1 other change: verification date
  2. Sep 29, 2026
    1 site added
    Show site
    • University of Chicago Medical Center /ID# 278863 · Chicago, United States
  3. Sep 28, 2026
    2 sites added, 1 site removed
    Show 2 added (1 China, 1 Japan)
    • The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 279207 · Hangzhou, China
    • The Cancer Institute Hospital Of Japanese Foundation for Cancer Research /ID# 279069 · Koto-ku, Japan
    Show 1 removed
    • The Cancer Institute Hospital Of JFCR /ID# 279069 · Koto-ku, Japan
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07409246
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Feb 13, 2026
Start date
Feb 27, 2026
Primary completion
Nov 2031 (estimated)
Completion
Nov 2031 (estimated)
Last update
Oct 20, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion